Assoz. Prof. Nuri Alper Şahbaz ist ein erfahrener Arzt mit medizinischer Ausbildung an der Medizinischen Fakultät der Cerrahpaşa-Universität Istanbul sowie wissenschaftlicher und klinischer Erfahrung am Baylor College of Medicine und der University of Texas Medical School. Er ist spezialisiert auf endokrine Chirurgie (Schilddrüsen-, Nebenschilddrüsen-, Nebennieren- und neuroendokrine Tumore) und hat in diesem Bereich über 2000 erfolgreiche Operationen durchgeführt. Er ist außerdem spezialisiert auf laparoskopische und minimal-invasive Operationen sowie auf diagnostische und therapeutische Endoskopie des Magen-Darm-Systems.
Mehr lesenAssoz. Prof. Nuri Alper Şahbaz ist ein erfahrener Arzt mit medizinischer Ausbildung an der Medizinischen Fakultät der Cerrahpaşa-Universität Istanbul sowie wissenschaftlicher und klinischer Erfahrung am Baylor College of Medicine und der University of Texas Medical School. Er ist spezialisiert auf endokrine Chirurgie (Schilddrüsen-, Nebenschilddrüsen-, Nebennieren- und neuroendokrine Tumore) und hat in diesem Bereich über 2000 erfolgreiche Operationen durchgeführt. Er ist außerdem spezialisiert auf laparoskopische und minimal-invasive Operationen sowie auf diagnostische und therapeutische Endoskopie des Magen-Darm-Systems.
Specializations
Diabetes (Sugar)
Thyroid
Hypertension
cholesterol
stomach diseases
intestinal diseases
osteoporosis
Experience
Azerbaijan Gusar Central Hospital
Vreden Russian Research Institute of Traumatology and Orthopedics
Azerbaijan Göranboy, First Lieutenant Doctor
Hospital Park Darıca Hospital
BAH
Education
Azerbaijan Medical Faculty (2015)
Kocaeli Derince Training and Research Hospital (2016-2020)
Vocational Trainings, Courses and Conferences Attended
Internal Medicine Congress
Gastro Academy
Mehr lesenSpecializations
Diabetes (Sugar)
Thyroid
Hypertension
cholesterol
stomach diseases
intestinal diseases
osteoporosis
Experience
Azerbaijan Gusar Central Hospital
Vreden Russian Research Institute of Traumatology and Orthopedics
Azerbaijan Göranboy, First Lieutenant Doctor
Hospital Park Darıca Hospital
BAH
Education
Azerbaijan Medical Faculty (2015)
Kocaeli Derince Training and Research Hospital (2016-2020)
Vocational Trainings, Courses and Conferences Attended
Internal Medicine Congress
Gastro Academy
Education:
Roles in Projects:
Sub investigator (Assistant Researcher) in the SOUL Study: Cardiovascular Outcome Research of Semaglutide in Type 2 Diabetic Patients, approved by the Turkish Medicines and Medical Devices Agency on May 22, 2019.
Sub investigator (Assistant Researcher) in the international study “SCALE™ Insulin”: Efficacy and Safety of Liraglutide 3.0 mg in Overweight or Obese Patients with Type 2 Diabetes Treated with Basal Insulin (Study Code: NN8022-4272), conducted by Novo Nordisk A.Ş.
Subinvestigator (Assistant Researcher) in the international study NN5401-4266 StepByStep Intensification conducted by Novo Nordisk.
Assistant Researcher in the study "A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)" (2019-2020).
Assistant Researcher in the PIONEER 1 study: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.
Mehr lesenEducation:
Roles in Projects:
Sub investigator (Assistant Researcher) in the SOUL Study: Cardiovascular Outcome Research of Semaglutide in Type 2 Diabetic Patients, approved by the Turkish Medicines and Medical Devices Agency on May 22, 2019.
Sub investigator (Assistant Researcher) in the international study “SCALE™ Insulin”: Efficacy and Safety of Liraglutide 3.0 mg in Overweight or Obese Patients with Type 2 Diabetes Treated with Basal Insulin (Study Code: NN8022-4272), conducted by Novo Nordisk A.Ş.
Subinvestigator (Assistant Researcher) in the international study NN5401-4266 StepByStep Intensification conducted by Novo Nordisk.
Assistant Researcher in the study "A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)" (2019-2020).
Assistant Researcher in the PIONEER 1 study: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.